Weston Brain Institute - Rapid Response: Parkinson's & Related Diseases

The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting high-risk, high-reward translational projects, while leveraging world-class business and scientific expertise in a fast and flexible granting process.

Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and economic costs to manage these diseases will rise significantly within a generation.

Meeting this challenge requires pioneering approaches to accelerating treatments. The Canada: Rapid Response program was created to provide seed funding for novel, high-risk, high-reward, translational research to accelerate the development of safe and effective treatments for neurodegenerative diseases of aging.

  • Parkinson’s disease 
  • Dementia with Lewy bodies 
  • Multiple system atrophy
  • Progressive supranuclear palsy
  • Vascular contributions to the above 
  • Prodromes to the above 
Key Dates
  • Program opens: May 4, 2018
  • LOI deadline: August 1, 2018 at 2:00pm EDT
  • Proposal deadline: November 12, 2018 at 2:00pm EST
  • Anticipated award notification: January 24, 2019

The Institute welcomes additional inquiries about this program, including whether a potential idea is in scope. For questions related to the Parkinson’s & Related Diseases program, please contact Matthew Sacheli.


Application Procedures

Please refer to the Weston Brain Institute website for application procedures.

Eligibility Summary

Applicant Eligibility: 

Eligible Principal Applicants must be researchers working in Canada at least 30% of the time at or above the level of Postdoctoral Fellow, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada.

If the Principal Applicant is not appointed at the institution from which they are applying, they need to apply with a research supervisor (an “Administrative Supervisor”) who is at or above the level of Assistant Professor or equivalent, with an appointment at the institution from which they are applying.

Applicants may appear in any role on any number of projects.

Project Eligibility: 

Projects must meet two conditions to be eligible:

  • Be translational research that helps accelerate the development of therapeutics for neurodegenerative diseases of aging
  • Be the development of a therapeutic and/or tool

*Preliminary or supporting data is not required for this program

Please refer to What We Fund for Institute definitions of neurodegenerative diseases of aging, translational research, therapeutic, and tool.


Wednesday, 1 August 2018

Annual Value